Entry Point Capital, LLC Ocugen, Inc. Transaction History
Entry Point Capital, LLC
- $221 Million
- Q4 2024
Shares
1 transactions
Others Institutions Holding OCGN
# of Institutions
126Shares Held
68.1MCall Options Held
634KPut Options Held
291K-
Black Rock Inc. New York, NY17.9MShares$12.9 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA16.6MShares$12 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA6.59MShares$4.74 Million0.0% of portfolio
-
State Street Corp Boston, MA5.87MShares$4.22 Million0.0% of portfolio
-
Gmt Capital Corp Atlanta, GA2.45MShares$1.77 Million0.1% of portfolio
About Ocugen, Inc.
- Ticker OCGN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 216,566,000
- Market Cap $156M
- Description
- Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on the developing gene therapies to cure blindness diseases. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, such as retinitis pigmento...